Shots:

• The two P-II/III studies involve assessing of Ajovy vs PBO in patients with chronic and episodic migraine respectively
• The two P-II/III studies resulted in meeting its 1EPs and 2EPs and is well tolerated. The results will serve as a basis to file MAA for PMDA’s approval in Japan
• Ajovy is the first and only anti-CGRP therapy- approved in the US and EU- indicated for the preventive treatment of migraine offering both quarterly and monthly dosing options- currently in development in Japan by Otsuka- under 2017 licensed agreement signed b/w the companies

Click here ­to­ read full press release/ article | Ref: Teva | Image: Teva